• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Optomed

1.70 EUR+2.05 %21.8. klo 18.29
5,676 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+2.05 %
0.00 %
+13.83 %
-39.21 %
-55.01 %
-54.41 %
-46.41 %
-87.15 %
-62.97 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
36.46M EUR
Turnover
48.21K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
17.08.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
So the missing piece with Big Pharma has been handled. Great.
yesterday
15
The Optomed USA website features a compilation of customer comments on using the Aurora camera in actual patient care. These are worth reading as they are based on real-world experience. Mentions of high image quality and ease of use, among other things, recur in these testimonials...
yesterday
by j.sälli
15
https://www.redeye.se/research/1180791/optomed-strong-h2-ahead
yesterday
by Bob Fleming
14
This deal with Big Pharma / AZ is invaluable to Optomed. Thanks to it, Optomed’s BRAND VALUE globally will rise to a whole new level, and this will facilitate all other business. Waiting for the news on the deal…
10 hours ago
by j.sälli
12
Now there’s finally some commentary on what was left out of the Inderes interview. BF is ready at the starting blocks, all the documents are ready, and the business plan is being polished. This is a binary case as well. As for the China JV, trials are underway and Wiser is handling...
yesterday
by Nakki Taskupiilo
12
There are many ways to interpret that. If you look at Himberg’s body language, things are cooking in the oven and moving forward. I wouldn’t be worried at all; it will definitely come through.
9 hours ago
by Dr.Feelgood
11
I listened to the Redeye interview. A Big Pharma partnership would also require investments from Optomed, and the revenue/returns are a long-term prospect. Everything is ready, but it is being considered. It doesn’t seem like Optomed is currently able to invest in that. The cash ...
11 hours ago
by Stallion
4
Read more on our forum
Juha Kinnunen
Juha Kinnunen

Analyst

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.11.
2026

Interim report Q3'26

18.2.
2027

Annual report '26

4.5.
2027

Interim report Q1'27

Press release18.08.2026 klo 14.10

Redeye: Optomed (Q2 Review): Sales miss offset by strong gross margin and cost control

Optomed
Regulatory press release14.08.2026 klo 13.00

Optomed Plc - Managers' transactions - Tauriainen

Optomed
Regulatory press release14.08.2026 klo 13.00

Optomed Plc - Managers' transactions - Leppänen

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release14.08.2026 klo 13.00

Optomed Plc - Managers' transactions - Wen

Optomed
Regulatory press release14.08.2026 klo 13.00

Optomed Plc - Managers' transactions - Salonen

Optomed
Regulatory press release14.08.2026 klo 13.00

Optomed Plc - Managers' transactions - Lee

Optomed
Regulatory press release14.08.2026 klo 13.00

Optomed Plc - Managers' transactions - Calarco

Optomed
Regulatory press release14.08.2026 klo 13.00

Optomed Plc - Managers' transactions - Badlani

Optomed
Regulatory press release14.08.2026 klo 13.00

Optomed Plc - Managers' transactions - Mäkinen

Optomed
Regulatory press release14.08.2026 klo 09.30

Optomed Oyj: Directed share issue without payment to implement Board remuneration

Optomed
Regulatory press release14.08.2026 klo 09.30

Optomed Oyj: Optomed's financial reporting in 2027

Optomed
Regulatory press release14.08.2026 klo 09.00

Optomed Plc: Half-year report January - June 2026

Optomed
Press release23.06.2026 klo 10.43

Redeye: Optomed: Solid device order

Optomed
Regulatory press release18.06.2026 klo 17.30

Inside Information: Optomed receives a large order in the US

Optomed
Press release11.05.2026 klo 16.16

Redeye: Optomed (Q1 Interview): Expecting normalised sales in upcoming quarters

Optomed
Regulatory press release08.05.2026 klo 20.00

Optomed Oyj: Decisions of the Organization Meeting of Optomed's Board of Directors

Optomed
Regulatory press release08.05.2026 klo 14.30

Optomed Oyj: Decisions of the Annual General Meeting

Optomed
Press release08.05.2026 klo 11.10

Redeye: Optomed (Q1 Review): Soft sales weigh on sentiment

Optomed
Press release06.05.2026 klo 11.51

Redeye: Optomed (Q1 Initial take): Softer quarter than expected

Optomed
Regulatory press release06.05.2026 klo 09.00

Optomed Oyj: Optomed Plc: Interim report January - March 2026

Optomed